1. Search Result
Search Result
Results for "

on

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

3

Natural
Products

19

Recombinant Proteins

2

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12338

    PI3K Bcr-Abl Cancer
    ON 146040 is a potent PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits Abl1 (IC50<150 nM).
    ON 146040
  • HY-156816

    Casein Kinase DYRK Cancer
    ON 108600 is a inhibitor for CK2 (Casein Kinase2)/TNIK/DYRK1 , with the IC50s for DYRK1A/DYRKB, DYRK2, CK2α1/CK2α2, and TNIK of 0.016 μm/0.007 μM, 0.028 μM, 0.05 μM/0.005 μM, and 0.005 μM, respectively. ON 108600 has antitumor activity .
    ON 108600
  • HY-101625
    Recilisib
    Maximum Cited Publications
    23 Publications Verification

    on 01210

    Akt PI3K Cancer
    Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells .
    Recilisib
  • HY-16366

    on 014185

    Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    Briciclib (ON 014185) is a derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.
    Briciclib
  • HY-112822
    ON-013100
    2 Publications Verification

    CDK Cancer
    ON-013100, an antineoplastic agent, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.
    ON-013100
  • HY-100789
    ON1231320
    1 Publications Verification

    Polo-like Kinase (PLK) Apoptosis Cancer
    ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 µM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity .
    ON1231320
  • HY-12037
    Rigosertib sodium
    5 Publications Verification

    on-01910 sodium

    Polo-like Kinase (PLK) PI3K Apoptosis Cancer
    Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM .
    Rigosertib sodium
  • HY-12037A
    Rigosertib
    5 Publications Verification

    on-01910

    Polo-like Kinase (PLK) PI3K Apoptosis Cancer
    Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM .
    Rigosertib
  • HY-101625A

    on 01210 sodium

    Akt PI3K Cancer
    Recilisib sodium (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells .
    Recilisib sodium
  • HY-164393

    JAK Bcr-Abl Apoptosis Cancer
    ON044580, an α-benzoyl styryl benzyl sulfide, is a potent and non-ATP-competitive JAK2 kinase inhibitor with IC50s of 1.23 μM, 1.09 μM for WT and V617F mutant JAK2, respectively. ON044580 inhibits the JAK2 kinase activity either by binding to the STAT-5 binding domain of JAK2 or by binding to an allosteric site. ON044580 exerts its antiproliferative effect in JAK2 V617F-positive leukemic cells. ON044580 effectively induces apoptosis of Imatinib (HY-15463)-resistant chronic myelogenous leukemia (CML) cells. ON044580 also inhibits both WT and T315I mutant forms of the BCR-ABL kinase. ON044580 has the potential for myeloproliferative disorders typified by aberrant JAK/STAT signaling .
    ON044580
  • HY-12624
    Narazaciclib
    2 Publications Verification

    on123300

    CDK AMPK PDGFR Cancer
    Narazaciclib (ON123300), a strong and brain-penetrant multi-kinase inhibitor, inhibits CDK4 (IC50=3.9 nM), Ark5 (IC50=5 nM), PDGFRβ (IC50=26 nM), FGFR1 (IC50=26 nM), RET (IC50=9.2 nM), and FYN (IC50=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors . Narazaciclib inhibits CDK6 with an IC50 of 9.82 nM .
    Narazaciclib
  • HY-18651

    (E/Z)-on-01910 sodium

    Polo-like Kinase (PLK) Others
    Rigosertib (ON-01910) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (E/Z)-Rigosertib sodium
  • HY-D0120

    7-(Isobutyloxycarbonyloxy)-3H-phenoxazin-3-on

    Fluorescent Dye Others
    CytoRed (7-(Isobutyloxycarbonyloxy)-3H-phenoxazin-3-on) is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely used in traditional fields such as textile dyeing, as well as in emerging fields such as functional textile processing, food pigments and dye-sensitized solar cells.
    CytoRed
  • HY-162376

    Bacterial Infection
    T3SS-IN-4 (Compound Z-8) is a T3SS inhibitor that can inhibit the expression of Xanthomonas oryzae pv oryzae (Xoo) T3SS-related genes without affecting bacterial growth. T3SS-IN-4 can effectively reduce the hypersensitive response (HR) induced by Xoo in tobacco and lower the pathogenicity of Xoo in rice .
    T3SS-IN-4
  • HY-B1779
    Sucrose
    5+ Cited Publications

    D-(+)-Saccharose

    Endogenous Metabolite Metabolic Disease Cancer
    Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al .
    Sucrose
  • HY-135773

    Prostaglandin Receptor PDK-1 Cardiovascular Disease Inflammation/Immunology
    CRTh2 antagonist 3 is a potent chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist . CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an EC50 of 2 μM and a Kd of 8.4 μM. CRTh2 antagonist 3 has the potential for cardiovascular inflammation .
    CRTh2 antagonist 3
  • HY-W768338

    D-(+)-Saccharose-13C

    Isotope-Labeled Compounds Metabolic Disease Cancer
    Sucrose- 13C is 13C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .
    Sucrose-13C
  • HY-W768340

    D-(+)-Saccharose-13C6-1

    Isotope-Labeled Compounds Metabolic Disease Cancer
    Sucrose- 13C6-1 is 13C labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .
    Sucrose-13C6-1
  • HY-B1779R

    Endogenous Metabolite Metabolic Disease Cancer
    Sucrose (Standard) is the analytical standard of Sucrose. This product is intended for research and analytical applications. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al .
    Sucrose (Standard)
  • HY-P99052
    Tislelizumab
    2 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-101563
    GSK3326595
    15+ Cited Publications

    EPZ015938

    Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis Infection Cancer
    GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
    GSK3326595
  • HY-111271
    L 888607
    1 Publications Verification

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a Ki value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite .
    L 888607
  • HY-111271B

    Others Inflammation/Immunology Endocrinology
    (R)-L 888607 is the isomer of L 888607 (HY-111271), and can be used as an experimental control. L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a Ki value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite .
    (R)-L 888607
  • HY-N15147

    DNA/RNA Synthesis Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Panax saponin C is a ginsenoside found in Ginseng with biological activities including regulatory effects on immunomodulation, protection functions in the central nervous and cardiovascular systems, anti-diabetic, anti-aging, anti-carcinogenic, anti-fatigue, anti-pyretic, anti-stress, boosting physical vitality, and promotion of DNA, RNA, and protein synthesis activities .
    Panax saponin C

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: